JP2014516029A5 - Rgシステイン酸ペプチドを含む治療剤 - Google Patents
Rgシステイン酸ペプチドを含む治療剤 Download PDFInfo
- Publication number
- JP2014516029A5 JP2014516029A5 JP2014510451A JP2014510451A JP2014516029A5 JP 2014516029 A5 JP2014516029 A5 JP 2014516029A5 JP 2014510451 A JP2014510451 A JP 2014510451A JP 2014510451 A JP2014510451 A JP 2014510451A JP 2014516029 A5 JP2014516029 A5 JP 2014516029A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- cysteic acid
- agent according
- formula
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims 34
- XVOYSCVBGLVSOL-UHFFFAOYSA-N Cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 title claims 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 230000002401 inhibitory effect Effects 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 230000033115 angiogenesis Effects 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- 230000001939 inductive effect Effects 0.000 claims 4
- 102000006495 integrins Human genes 0.000 claims 4
- 108010044426 integrins Proteins 0.000 claims 4
- 241000894006 Bacteria Species 0.000 claims 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 3
- 208000010412 Glaucoma Diseases 0.000 claims 3
- 208000002780 Macular Degeneration Diseases 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 229940079593 drugs Drugs 0.000 claims 3
- 230000001613 neoplastic Effects 0.000 claims 3
- 210000001519 tissues Anatomy 0.000 claims 3
- 206010064930 Age-related macular degeneration Diseases 0.000 claims 2
- 102000005600 Cathepsins Human genes 0.000 claims 2
- 108010084457 Cathepsins Proteins 0.000 claims 2
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 2
- 210000001328 Optic Nerve Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 201000000159 corneal neovascularization Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002708 enhancing Effects 0.000 claims 2
- 230000000302 ischemic Effects 0.000 claims 2
- 230000004380 optic nerve Effects 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 206010000496 Acne Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000006673 Asthma Diseases 0.000 claims 1
- 229940120638 Avastin Drugs 0.000 claims 1
- 206010060945 Bacterial infection Diseases 0.000 claims 1
- 108010005144 Bevacizumab Proteins 0.000 claims 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 229940039227 DIAGNOSTIC AGENTS Drugs 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 241000255925 Diptera Species 0.000 claims 1
- 206010014071 Ebola disease Diseases 0.000 claims 1
- 201000011001 Ebola hemorrhagic fever Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 210000000554 Iris Anatomy 0.000 claims 1
- 206010065630 Iris neovascularisation Diseases 0.000 claims 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims 1
- 229940076783 Lucentis Drugs 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010051058 Macular hole Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 206010027476 Metastasis Diseases 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 229940074730 OPHTHAMOLOGIC DIAGNOSTIC AGENTS Drugs 0.000 claims 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 1
- 229960003876 Ranibizumab Drugs 0.000 claims 1
- 108010062724 Ranibizumab Proteins 0.000 claims 1
- 206010038848 Retinal detachment Diseases 0.000 claims 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 1
- 206010039580 Scar Diseases 0.000 claims 1
- 208000008742 Seborrheic Dermatitis Diseases 0.000 claims 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims 1
- 206010043189 Telangiectasia Diseases 0.000 claims 1
- 208000009056 Telangiectasis Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010043778 Thyroiditis Diseases 0.000 claims 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 1
- 208000009443 Vascular Malformations Diseases 0.000 claims 1
- 210000003462 Veins Anatomy 0.000 claims 1
- 206010058990 Venous occlusion Diseases 0.000 claims 1
- 206010047461 Viral infection Diseases 0.000 claims 1
- 208000001756 Virus Disease Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229960002833 aflibercept Drugs 0.000 claims 1
- 108010081667 aflibercept Proteins 0.000 claims 1
- 229930002945 all-trans-retinaldehyde Natural products 0.000 claims 1
- 230000000259 anti-tumor Effects 0.000 claims 1
- 201000007917 background diabetic retinopathy Diseases 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 230000002497 edematous Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000813 microbial Effects 0.000 claims 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 claims 1
- 230000023578 negative regulation of cell adhesion Effects 0.000 claims 1
- 230000013152 negative regulation of cell migration Effects 0.000 claims 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 claims 1
- 201000003142 neovascular glaucoma Diseases 0.000 claims 1
- 230000001717 pathogenic Effects 0.000 claims 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 201000002154 pterygium Diseases 0.000 claims 1
- 230000002207 retinal Effects 0.000 claims 1
- 235000020945 retinal Nutrition 0.000 claims 1
- 239000011604 retinal Substances 0.000 claims 1
- 201000007737 retinal degeneration Diseases 0.000 claims 1
- 230000004258 retinal degeneration Effects 0.000 claims 1
- 230000004264 retinal detachment Effects 0.000 claims 1
- 201000011056 retinal disease Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 230000037387 scars Effects 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 231100001005 telangiectasia Toxicity 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 230000006711 vascular endothelial growth factor production Effects 0.000 claims 1
- 230000017613 viral reproduction Effects 0.000 claims 1
- 230000003612 virological Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Claims (22)
- ヒト、又は動物の対象者において、a)少なくとも一つのインテグリンとの治療上の結合若しくは少なくとも一つインテグリンの阻害を引き起こすこと、b)腫瘍性疾患若しくは新生物疾患を治療すること、c)腫瘍組織若しくは新生物組織を標識すること、d)ウイルス若しくは他の細菌の感染症を治療すること、e)別の薬剤の作用の効果を高める若しくは作用を持続すること、或いはf)チロシンキナーゼを阻害すること、のいずれかのための治療剤であって、RGシステイン酸ペプチドを含む治療剤。
- 前記治療剤は、α 3 β 1 −インテグリン、α 5 β 1 −インテグリン、α v β 3 −インテグリンおよびα v β 5 −インテグリンのうちの少なくとも一つの阻害を引き起こす、請求項1に記載の治療剤。
- 前記治療剤は、
エンドソームカテプシンの調節、微生物(細菌またはウイルス)感染の治療または予防、細胞内に侵入する病原菌(細菌またはウイルス)の阻止、血管形成の阻害の治療または阻止、血管形成に関連する疾患の治療または予防、腫瘍もしくは新生物の血管形成または血管新生の阻害、VEGFの産生または利用の阻害、細胞の接着、移動および増殖のうちの少なくとも一方の阻害、炎症の治療、癌の治療、転移の治療、治療薬または診断用薬の腫瘍への誘導または送達、血栓症の治療、硝子体索切断の誘起、硝子体網膜剥離の誘起、硝子体切除の性能の助長、創傷治癒の促進、特定のインテグリンを発現する組織の放射性同位体標識、および緑内障の治療のうちから選択される治療効果をもたらすためにインテグリンの阻害を引き起こすためのものである、請求項1に記載の治療剤。 - 前記治療剤は、癌、血管奇形、動脈硬化症、血管接着、浮腫性硬化症、角膜移植片新生血管形成、血管新生緑内障、糖尿病性網膜症、翼状片、網膜変性、萎縮型(dry)および滲出型黄斑変性、黄斑浮腫、飛蚊症、角膜血管新生、虚血性視神経、虹彩血管新生、中心静脈閉塞、網膜上膜の剥離、水晶体後線維増殖、顆粒性結膜炎、関節リウマチ、全身性エリテマトーデス、甲状腺炎、乾癬、喘息、毛細血管拡張、化膿性肉芽腫、脂漏性皮膚炎、およびざ瘡のうちから選択される血管形成に関連する疾患または不調を治療するためにインテグリンの阻害を引き起こすためのものである、請求項1に記載の治療剤。
- 前記RGシステイン酸ペプチドは下記一般式を有し、
- 前記RGシステイン酸ペプチドは下記一般式を有し、
- 前記RGシステイン酸ペプチドは下記一般式を有し、
- 前記RGシステイン酸ペプチドは下記一般式を有し、
- 前記RGシステイン酸ペプチドは下記一般式を有し、
- 前記RGシステイン酸ペプチドは下記一般式を有し、
- 前記RGシステイン酸ペプチドは下記一般式を有し、
X1−R−G−システイン酸−X
前記式中、XおよびX1は環状または直鎖状の−Phe−Val−Ala、−Phe−Leu−Ala、−Phe−Val−Gly、−Phe−Leu−Gly、−Phe−Pro−Gly、−Phe−Pro−Ala、−Phe−Val、またはArg、Gly、システイン酸、Phe、Val、Ala、Leu、Pro、ThrのD−異性体もしくはL−異性体の任意の組み合わせの任意の塩のうちから選択される、請求項1に記載の治療剤。 - 前記RGシステイン酸ペプチドは下記一般式を有し、
- 前記RGシステイン酸ペプチドは、多量体RGシステイン酸ペプチドを含む、請求項1に記載の治療剤。
- 前記多量体RGシステイン酸ペプチドは抗腫瘍物質に結合される、請求項13に記載の治療剤。
- 前記多量体RGシステイン酸ペプチドは下式
- 前記多量体RGシステイン酸ペプチドは腫瘍組織を放射性標識するために放射性標識された化合物に結合される、請求項13に記載の治療剤。
- 放射性標識された化合物に結合した前記多量体RGシステイン酸ペプチドは下式
- 前記治療剤はエボラウイルス感染症又は別のウイルス感染症を治療するためのものである、請求項1に記載の治療剤。
- 前記治療剤は、対象者の身体の細胞内へのウイルスの侵入を抑止するような方法でエンドソームのカテプシンをレギュレートする投与量で投与される、請求項1又は18に記載の治療剤。
- 前記治療剤は、既に産生されたVEGFを結合する、捕捉する、除去する、または他の場合には前記VEGFの効果を抑止する1つ以上の別の薬剤の作用の効果を高める若しくは作用を持続するために投与される、請求項1に記載の治療剤。
- 前記1つ以上の別の薬剤は、ベバシズマブ(アバスチン)、ラニビズマブ(ルセンティス)およびアフリベルセプト(アイリーア)のうちから選択される少なくとも1つの薬剤を含む、請求項20に記載の治療剤。
- 前記治療剤は、滲出型加齢性黄斑変性、糖尿病性黄斑浮腫、増殖性または非増殖性糖尿病性網膜症、硝子体液の液化、後部硝子体網膜剥離(PVD)の誘発、特発性黄斑円孔、硝子体黄斑牽引、加齢性黄斑変性、脈絡膜血管新生のような硝子体網膜疾患の病因、硝子体網膜手術、静脈閉塞、角膜血管新生、虚血性視神経、虹彩血管新生、および緑内障手術における瘢痕生成の防止を治療するためのものである、請求項1、20及び21のいずれか一項に記載の治療剤。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161484194P | 2011-05-09 | 2011-05-09 | |
US61/484,194 | 2011-05-09 | ||
US201161486195P | 2011-05-13 | 2011-05-13 | |
US61/486,195 | 2011-05-13 | ||
US201261643118P | 2012-05-04 | 2012-05-04 | |
US61/643,118 | 2012-05-04 | ||
PCT/US2012/037177 WO2012154894A2 (en) | 2011-05-09 | 2012-05-09 | Integrin receptor antagonists and their methods of use |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017040516A Division JP6383031B2 (ja) | 2011-05-09 | 2017-03-03 | R−g−システイン酸ペプチドを含む医薬組成物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014516029A JP2014516029A (ja) | 2014-07-07 |
JP2014516029A5 true JP2014516029A5 (ja) | 2015-06-25 |
JP6106159B2 JP6106159B2 (ja) | 2017-03-29 |
Family
ID=47139985
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014510451A Active JP6106159B2 (ja) | 2011-05-09 | 2012-05-09 | R−g−システイン酸ペプチドを含む医薬組成物 |
JP2017040516A Active JP6383031B2 (ja) | 2011-05-09 | 2017-03-03 | R−g−システイン酸ペプチドを含む医薬組成物 |
JP2018146060A Revoked JP6788154B2 (ja) | 2011-05-09 | 2018-08-02 | R−g−システイン酸ペプチドを含む医薬組成物 |
JP2020130450A Active JP7197199B2 (ja) | 2011-05-09 | 2020-07-31 | 新血管形成または血管形成を阻害することによって腫瘍形成を防止するための医薬組成物 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017040516A Active JP6383031B2 (ja) | 2011-05-09 | 2017-03-03 | R−g−システイン酸ペプチドを含む医薬組成物 |
JP2018146060A Revoked JP6788154B2 (ja) | 2011-05-09 | 2018-08-02 | R−g−システイン酸ペプチドを含む医薬組成物 |
JP2020130450A Active JP7197199B2 (ja) | 2011-05-09 | 2020-07-31 | 新血管形成または血管形成を阻害することによって腫瘍形成を防止するための医薬組成物 |
Country Status (15)
Country | Link |
---|---|
US (2) | US9896480B2 (ja) |
EP (2) | EP3243530B1 (ja) |
JP (4) | JP6106159B2 (ja) |
KR (2) | KR102165421B1 (ja) |
CN (1) | CN104080467B (ja) |
AU (5) | AU2012253511A1 (ja) |
BR (1) | BR112013028914B1 (ja) |
CA (1) | CA2835214C (ja) |
ES (1) | ES2820855T3 (ja) |
HK (1) | HK1202449A1 (ja) |
IL (1) | IL229299A0 (ja) |
MX (1) | MX2013012953A (ja) |
RU (1) | RU2721907C2 (ja) |
WO (1) | WO2012154894A2 (ja) |
ZA (1) | ZA201308325B (ja) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011060104A2 (en) | 2009-11-10 | 2011-05-19 | Allegro Pharmaceuticals, Inc. | Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to rgd binding sites |
US11673914B2 (en) | 2009-11-10 | 2023-06-13 | Allegro Pharmaceuticals, LLC | Peptide therapies for reduction of macular thickening |
KR102165421B1 (ko) * | 2011-05-09 | 2020-10-14 | 알레그로 파마슈티칼스, 인코포레이티드. | 인테그린 수용체 길항물질 및 이의 사용 방법 |
DK2953948T3 (en) | 2013-02-07 | 2017-12-18 | Scifluor Life Sciences Inc | FLUORINATED INTEGRIN ANTAGONISTS |
US8901144B2 (en) | 2013-02-07 | 2014-12-02 | Scifluor Life Sciences, Llc | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives |
RU2017132433A (ru) | 2015-02-19 | 2019-03-19 | Сайфлуор Лайф Сайенсиз, Инк. | Фторированные производные тетрагидронафтиридинилнонановой кислоты и их применение |
AU2016365312A1 (en) * | 2015-12-04 | 2018-05-24 | Janssen Biotech, Inc. | Treatment of retinal degeneration using progenitor cells |
CN105837666A (zh) * | 2015-12-30 | 2016-08-10 | 田梗 | 一种用于诊断糖尿病性视网膜病的蛋白质 |
EP3518913A4 (en) * | 2016-09-29 | 2020-05-27 | NatureWise Biotech & Medicals Corporation | METHODS OF TREATING EYE DISEASE |
EP3551211B1 (en) * | 2016-12-12 | 2021-09-01 | Sorbonne Université | Lebecetin, a c-type lectin, as neovascularization inhibitor |
MX2019008621A (es) * | 2017-01-19 | 2020-01-21 | Allegro Pharmaceuticals Llc | Peptidos terapeuticos y neuroprotectores. |
EP4389216A2 (en) * | 2017-06-19 | 2024-06-26 | Allegro Pharmaceuticals, LLC | Peptide compositions and therapeutic uses |
CN111658647A (zh) * | 2019-03-08 | 2020-09-15 | 首都医科大学宣武医院 | 沙利度胺及其衍生物的用途 |
CN114173802A (zh) * | 2019-07-26 | 2022-03-11 | 急速制药有限责任公司 | 用于治疗非渗出性黄斑变性和其他眼睛病症的肽 |
US20210275624A1 (en) * | 2020-03-06 | 2021-09-09 | Allegro Pharmaceuticals, LLC | Treatments for improving or lessening impairment of mitochondrial function |
WO2022183360A1 (en) * | 2021-03-02 | 2022-09-09 | Tsao Yeou Ping | Short synthetic peptide and their uses for treating dry eye disease |
CN116059312A (zh) * | 2021-07-23 | 2023-05-05 | 百奥泰生物制药股份有限公司 | 整合素GPIIb/IIIa拮抗剂及其和抗VEGF抗体联合用药的应用 |
CN117771376B (zh) * | 2024-02-26 | 2024-05-03 | 四川大学华西第二医院 | 一类化合物在注意缺陷与多动障碍中的应用及产品 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4517686A (en) | 1982-08-04 | 1985-05-21 | La Jolla Cancer Research Foundation | Polypeptide |
US4614517A (en) | 1982-08-04 | 1986-09-30 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4589881A (en) | 1982-08-04 | 1986-05-20 | La Jolla Cancer Research Foundation | Polypeptide |
US4661111A (en) | 1982-08-04 | 1987-04-28 | La Jolla Cancer Research Foundation | Polypeptide |
US4578079A (en) | 1982-08-04 | 1986-03-25 | La Jolla Cancer Research Foundation | Tetrapeptide |
US5635477A (en) * | 1991-09-30 | 1997-06-03 | The Dupont Merck Pharmaceutical Company | Cyclic compounds useful as inhibitors of platelet glycoprotein IIB/IIIA |
JPH08508498A (ja) | 1993-03-29 | 1996-09-10 | ザ・デュポン・メルク・ファーマシュウティカル・カンパニー | 血小板糖タンパク質▲II▼b/▲III▼aの阻害剤として有用な環状化合物 |
US6346604B1 (en) | 1995-10-31 | 2002-02-12 | Takeda Chemical Industries, Inc. | Method for controlling conformation of cyclopentapeptide |
AU2958195A (en) | 1994-06-29 | 1996-01-25 | Texas Biotechnology Corporation | Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin |
JPH08119991A (ja) | 1994-10-24 | 1996-05-14 | Otsuka Pharmaceut Factory Inc | ペプチド誘導体及びil−1産生抑制剤 |
US6551574B2 (en) | 1995-06-07 | 2003-04-22 | Rhomed Incorporated | Tuftsin metallopeptide analogs and uses thereof |
US6610292B2 (en) | 1995-11-22 | 2003-08-26 | Ista Pharmaceuticals, Inc. | Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders |
SK163298A3 (en) | 1996-05-31 | 1999-07-12 | Scripps Research Inst | Methods and compositions useful for inhibition of 'alpha'v'beta'5 mediated angiogenesis |
US6331285B1 (en) * | 1996-06-05 | 2001-12-18 | Palatin Technologies, Inc. | Structurally determined cyclic metallo-constructs and applications |
US20030170250A1 (en) | 1998-03-23 | 2003-09-11 | Ezrin Alan M. | Local delivery of long lasting therapeutic agents |
AU4057799A (en) | 1998-05-29 | 1999-12-20 | St. Marianna University School Of Medicine | T cell antigen receptor sequences specific to arthrosis deformans |
US7030211B1 (en) | 1998-07-08 | 2006-04-18 | Gemvax As | Antigenic peptides derived from telomerase |
US7070936B1 (en) | 1999-01-13 | 2006-07-04 | The Research Foundation Of State University Of New York | Method for designing protein kinase inhibitors |
WO2000042213A1 (en) | 1999-01-13 | 2000-07-20 | The Research Foundation Of State University Of New York | A novel method for designing protein kinase inhibitors |
US20040072315A1 (en) * | 2001-02-05 | 2004-04-15 | Xinjie Lu | Integrin-binding chimeras |
WO2002067972A1 (en) * | 2001-02-28 | 2002-09-06 | Duke University | Method of inducing vitreous detachment |
JP2002326949A (ja) | 2001-05-02 | 2002-11-15 | Kansai Tlo Kk | 免疫賦活剤 |
US7906102B2 (en) | 2001-10-03 | 2011-03-15 | Vanderbilt University | Ligands to radiation-induced molecules |
WO2003037172A2 (en) | 2001-11-01 | 2003-05-08 | Gpc Biotech Inc. | Endothelial-cell binding peptides for diagnosis and therapy |
WO2006017619A2 (en) | 2004-08-06 | 2006-02-16 | The Regents Of The University Of California | Receptor-binding cyclic peptides and methods of use |
US20090110662A1 (en) | 2007-04-30 | 2009-04-30 | Intezyne Technologies, Inc. | Modification of biological targeting groups for the treatment of cancer |
EP2147016A2 (en) | 2007-05-16 | 2010-01-27 | ConjuChem Biotechnologies Inc. | Cysteic acid derivatives of anti-viral peptides |
WO2011060104A2 (en) * | 2009-11-10 | 2011-05-19 | Allegro Pharmaceuticals, Inc. | Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to rgd binding sites |
KR102165421B1 (ko) | 2011-05-09 | 2020-10-14 | 알레그로 파마슈티칼스, 인코포레이티드. | 인테그린 수용체 길항물질 및 이의 사용 방법 |
-
2012
- 2012-05-09 KR KR1020197025906A patent/KR102165421B1/ko active IP Right Grant
- 2012-05-09 AU AU2012253511A patent/AU2012253511A1/en not_active Abandoned
- 2012-05-09 EP EP17159955.8A patent/EP3243530B1/en active Active
- 2012-05-09 EP EP12782195.7A patent/EP2707036A4/en not_active Withdrawn
- 2012-05-09 JP JP2014510451A patent/JP6106159B2/ja active Active
- 2012-05-09 MX MX2013012953A patent/MX2013012953A/es active IP Right Grant
- 2012-05-09 CA CA2835214A patent/CA2835214C/en active Active
- 2012-05-09 US US13/467,995 patent/US9896480B2/en active Active
- 2012-05-09 BR BR112013028914-7A patent/BR112013028914B1/pt active IP Right Grant
- 2012-05-09 CN CN201280034143.3A patent/CN104080467B/zh active Active
- 2012-05-09 ES ES17159955T patent/ES2820855T3/es active Active
- 2012-05-09 WO PCT/US2012/037177 patent/WO2012154894A2/en active Application Filing
- 2012-05-09 KR KR1020137032421A patent/KR102019970B1/ko active IP Right Grant
- 2012-05-09 RU RU2013153152A patent/RU2721907C2/ru active
-
2013
- 2013-11-06 ZA ZA2013/08325A patent/ZA201308325B/en unknown
- 2013-11-07 IL IL229299A patent/IL229299A0/en active IP Right Grant
-
2015
- 2015-03-30 HK HK15103165.6A patent/HK1202449A1/xx unknown
-
2017
- 2017-03-03 JP JP2017040516A patent/JP6383031B2/ja active Active
- 2017-06-21 AU AU2017204193A patent/AU2017204193A1/en not_active Abandoned
-
2018
- 2018-01-10 US US15/867,139 patent/US10590166B2/en active Active
- 2018-08-02 JP JP2018146060A patent/JP6788154B2/ja not_active Revoked
- 2018-11-14 AU AU2018264033A patent/AU2018264033B2/en active Active
-
2020
- 2020-07-31 JP JP2020130450A patent/JP7197199B2/ja active Active
- 2020-10-08 AU AU2020250268A patent/AU2020250268B2/en active Active
-
2023
- 2023-02-10 AU AU2023200742A patent/AU2023200742A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014516029A5 (ja) | Rgシステイン酸ペプチドを含む治療剤 | |
JP5739908B2 (ja) | 血管形成関連の眼疾患の処置のための組成物および方法 | |
US10035850B2 (en) | Methods for treating neovascular age-related macular degeneration | |
EP4317185A3 (en) | Fully-human post-translationally modified antibody therapeutics | |
JP2014532072A5 (ja) | ||
CN107427476A (zh) | 作为免疫调节剂的3‑取代的‑1,2,4‑噁二唑和噻二唑化合物 | |
CN107427497A (zh) | 作为免疫调节剂的3‑取代的1,3,4‑噁二唑和噻二唑化合物 | |
CA3111217A1 (en) | Methods of treating cytokine release syndrome | |
RU2013153152A (ru) | Антагонисты интегриновых рецепторов и их применение | |
WO2009055742A3 (en) | Delivery of active agents | |
WO2006130034A1 (fr) | Procede pour prolonger la duree de vie d'animaux ou de l'humain | |
CN108601767A (zh) | 用谷氨酰胺酶抑制剂和免疫肿瘤学药剂的组合疗法 | |
EP1758998A4 (en) | OLIGORIBONUCLEOTIDES AND METHODS OF USE THEREOF IN THE TREATMENT OF FIBROUS CONDITIONS AND OTHER DISEASES | |
US20180221405A1 (en) | Silicate containing compositions and methods of treatment | |
RU2020129180A (ru) | Терапевтический биопрепарат для лечения гепатоцеллюлярной карциномы | |
JP2015520188A5 (ja) | ||
RU2652605C2 (ru) | Блокада воспалительных протеаз тета-дефензинами | |
JP2006513217A (ja) | 眼内用途のためのステロイド組成物 | |
JP2015096065A5 (ja) | ||
Hakim et al. | Gene therapy strategies for glaucoma from IOP reduction to retinal neuroprotection: Progress towards non-viral systems | |
Wu et al. | Suprachoroidal injection: a novel approach for targeted drug delivery | |
WO2004024089A3 (en) | Inhibition or activation of adam9 and adam15 for treatment of vascularization-related disease and wound healing | |
US11564907B2 (en) | Methods and compositions for the treatment of retinopathy and other ocular diseases | |
JP2019507193A (ja) | 細菌のバイオフィルム形成を阻止又は妨害することによって眼障害を治療する方法 | |
JP2023099171A (ja) | 緑内障を治療するためのWnt5aの調節 |